Podcasts about medical oncology

Branch of medicine dealing with cancer

  • 291PODCASTS
  • 924EPISODES
  • 28mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • Aug 27, 2025LATEST
medical oncology

POPULARITY

20172018201920202021202220232024


Best podcasts about medical oncology

Show all podcasts related to medical oncology

Latest podcast episodes about medical oncology

OncLive® On Air
S14 Ep2: FDA Approval Insights: Zongertinib in HER2-Mutated NSCLC: With Ticiana Leal, MD, and Misako Nagasaka, MD, PhD

OncLive® On Air

Play Episode Listen Later Aug 27, 2025 15:43


In today's episode, supported by Boehringer Ingelheim, we spoke with Ticiana Leal, MD, and Misako Nagasaka, MD, PhD, about the FDA approval of zongertinib (Hernexeos) for previously treated patients with HER2 TKD–mutant advanced non–small cell lung cancer (NSCLC). Dr Leal is an associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia; as well as medical director of the Clinical Trials Office and leader of the Lung Cancer Disease Team at the Winship Cancer Institute of Emory University. Dr Nagasaka is an associate professor of medicine in the Division of Hematology and Oncology at the University of California, Irvine (UCI) School of Medicine; as well as a medical oncologist at UCI Health. In our conversation, Drs Leal and Nagasaka discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1 Beamion LUNG-1 trial (NCT04886804), and where zongertinib currently fits into the NSCLC treatment paradigm.

OncLive® On Air
S13 Ep46: FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD

OncLive® On Air

Play Episode Listen Later Aug 18, 2025 12:38


In today's episode, we spoke with Nisha Joseph, MD, and Hans Lee, MD, about the FDA's accelerated approval of linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 4 or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Joseph is an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia. Lee is the director of Myeloma Research at the Sarah Cannon Research Institute in Nashville, Tennessee.  In our conversation, Drs Lee and Joseph discussed the significance of this approval, key data from the pivotal phase 1/2 LINKER-MM1 trial (NCT03761108), and where linvoseltamab fits into the relapsed/refractory myeloma treatment paradigm alongside other approved agents. 

OncLive® On Air
S13 Ep44: Frank's Path to Advancing Hematology Through Innovation and Discovery: With Girindra Raval, MD; and David A. Frank, MD, PhD, FACP

OncLive® On Air

Play Episode Listen Later Aug 13, 2025 40:56


In this episode, Raval welcomed David A. Frank, MD, PhD, FACP, who is director of the Division of Hematology and a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as director of the Winship Innovation Initiative and as an advisor to the Morningside Center for Innovative and Affordable Medicine within the Woodruff Health Sciences Center.

QuadShot News Podcast
8.11.2025 - The FLAME keeps burning

QuadShot News Podcast

Play Episode Listen Later Aug 11, 2025 8:47


Check out this week's QuadCast as we highlight long term results from FLAME on DIL SIB in prostate cancer, how the benefits of Pluvicto are growing, the thought provoking question of surgical omission in breast cancer, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Project Oncology®
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care

Project Oncology®

Play Episode Listen Later Aug 6, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it's also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it's important to know how and when to test for this mutation and how emerging targeted therapies might change our approach in clinical practice. Joining Dr. Charles Turck to share her insights on PI3Kα testing and targeted therapies for HR+/HER2- advanced breast cancer is Dr. Hope Rugo, Director of the Women's Cancers Program, Division Chief of Breast Medical Oncology and Professor of the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center.

QuadShot News Podcast
7.28.2025 - Just Swell

QuadShot News Podcast

Play Episode Listen Later Jul 28, 2025 9:10


Check out this week's QuadCast as we highlight the impact of perilesional edema on local failure risk for brain SRS, the benefits of RT in high risk prostate cancer, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Lung Cancer Considered
Preview: IASLC | ASCO 2025 North American Conference on Lung Cancer

Lung Cancer Considered

Play Episode Listen Later Jul 23, 2025 22:40


On December 5, 2025, we will kick off the IASLC ASCO 2025 North America Conference on Lung Cancer. Guest include Dr. Ramesh Rengan, the Peter Wootton Professor and Chair of Radiation Oncology at the University of Washington and Senior Vice President of the Fred Hutchinson Cancer Center and Dr. Kristen Marrone, Associate Professor of Oncology and Director of the Medical Oncology and Hematology Fellowship Program at Johns Hopkins University.

Oncology Peer Review On-The-Go
S1 Ep171: Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Oncology Peer Review On-The-Go

Play Episode Listen Later Jul 21, 2025 19:04


In this episode, CancerNetwork® spoke with breast oncologists Heather McArthur, MD; Erika Hamilton, MD; Hope Rugo, MD; and Paolo Tarantino, MD, PhD, about advances in breast cancer. These developments included recent drug approvals and ongoing research for therapeutic approaches, particularly in the areas of antibody-drug conjugates (ADCs) and CDK4/6 inhibitors, based on presentations they gave at the 25th Annual International Congress on the Future of Breast Cancer (IBC) East in New York City. Initially, McArthur, Komen Distinguished Chair in Clinical Breast Cancer Research at the Harold C. Simmons Comprehensive Cancer Center, discussed immunotherapy use in high-risk triple-negative and HER2-positive disease, the evolving role of adjuvant CDK4/6 inhibition in HER2-negative breast cancer, and potentially transformative advancements in early breast cancer treatment.  She highlighted the FDA approval for pembrolizumab (Keytruda) in early-stage triple-negative breast cancer, promising clinical trials in estrogen receptor (ER)–positive high-risk early-stage breast cancer, and data from an investigator-initiated trial to treat HER2-positive disease. Additionally, she highlighted an 8.5% improvement in pathological complete response with pembrolizumab added to immunotherapy in the phase 3 KEYNOTE-756 trial (NCT03725059), adding that a further event-free survival benefit may complicate the landscape for CDK4/6 inhibition based on lung and liver toxicities associated with the coadministration of these inhibitors with immunotherapy.1 McArthur expressed further excitement for ADC-based combinations for triple-negative disease, as well as in the high-risk residual disease setting. In addition, she highlighted potential advancements in de-escalation strategies and further considerations for ADCs in the HER2-positive and hormone receptor (HR)–positive spaces. Then, Hamilton, director of Breast Cancer and Gynecologic Cancer Research at the Sarah Cannon Research Institute, highlighted emerging therapies for early breast cancer, as well as her use of datopotamab deruxtecan-dlnk (dato-DXd; Datroway) and fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) given their recent approvals in various breast cancer subtypes. She also touched upon challenges with respect to the implementation of new therapies for early breast cancer into clinical practice. She initially highlighted new data from the phase 3 VERITAC-2 trial (NCT05654623) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.2 Specifically, findings showed that vepdegestrant, an oral proteolysis-targeting chimera (PROTAC), exhibited an efficacy advantage over fulvestrant (Faslodex) in patients with ESR1-mutant ER-positive, HER2-negative advanced or metastatic disease. Moreover, she highlighted data from the phase 3 DESTINY-Breast09 (NCT04784715) of T-DXd in various combinations for patients with HER2-positive metastatic breast cancer.3 Hamilton further highlighted her implementation of T-DXd into clinical practice, citing her use of the agent in patients with metastatic disease, including those with HER2-low and HER2-ultralow breast cancer. She further differentiated dato-DXd from T-DXd, suggesting that they were different classes of drugs due to their different targets: TROP2 vs HER2. She concluded by highlighting an unmet need regarding sustained benefit from endocrine therapy in HR-positive disease, as well as for ADC sequencing and mechanisms of resistance. Afterward, Rugo, division chief of Breast Medical Oncology, Women's Cancer Program Director, and professor in the Department of Medical Oncology and Therapeutics Research at City of Hope, discussed efficacy and safety considerations for CDK4/6 inhibitors in early breast cancer treatment. Specifically, she highlighted their high tolerability despite adverse effects and costs associated with their use. Rugo further touched upon a reduction of recurrence rates associated with CDK4/6 inhibition, although longer-term follow-up data were warranted to optimize the duration of therapy and elucidate survival outcomes. Finally, Tarantino, a research fellow at the Dana-Farber Institute, concluded by discussing sequencing strategies for ADCs, as well as which breast cancer settings or patient populations will experience the greatest impact with this treatment modality. Tarantino discussed his use of the “sandwich strategy,” where he switches the mechanism of action of treatment after using a TOPO1 ADC. Furthermore, Tarantino highlighted data from the DESTINY-Breast09 and phase 3 ASCENT-04 (NCT06100874) trials, which displayed the enhanced efficacy of 2 ADC combination therapies.4 He concluded by discussing future considerations for combining multiple ADCs. References 1. Cardoso F, O'Shaughnessy J, Liu Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025;31(2):442-448. doi:10.1038/s41591-024-03415-7 2. Hamilton E, De Laurentiis M, Jhaveri K, et al. Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: results of the global, randomized, phase 3 VERITAC-2 study. J Clin Oncol. 2025;43(suppl 17):LBA1000. doi:10.1200/JCO.2025.43.17_suppl.LBA1000 3. Tolaney S, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): interim results from DESTINY-Breast09. J Clin Oncol. 2025;43(suppl 17):LBA1008. 4. Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study. J Clin Oncol. 2025;43(suppl 17):LBA109. doi:10.1200/JCO.2025.43.17_suppl.LBA109

QuadShot News Podcast
7.14.2025 - VIOLET

QuadShot News Podcast

Play Episode Listen Later Jul 14, 2025 7:50


Check out this week's QuadCast as we highlight a PSMA Theranostic contender, new guidelines (and name) for GBM, current management limitations in NSCLC, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

OncLive® On Air
S13 Ep28: Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

OncLive® On Air

Play Episode Listen Later Jul 10, 2025 11:20


In today's episode, supported by Coherus BioSciences, we had the pleasure of speaking with Justine Bruce, MD, about the ongoing evolution of nasopharyngeal carcinoma management. Dr Bruce is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at the University of Wisconsin, as well as the director of the VA Medical Oncology Clinical Research Program and chair of the Protocol Review and Monitoring Committee at the University of Wisconsin Carbone Cancer Center in Madison. In our exclusive interview, Dr Bruce discussed evolving treatment strategies for nasopharyngeal cancer, emphasizing the shift from chemoradiation followed by adjuvant chemotherapy to induction chemotherapy with gemcitabine and cisplatin. She also noted how toripalimab-tpzi (Loqtorzi) combined with gemcitabine and cisplatin showed improved overall survival (OS) in the first-line setting in the phase 3 JUPITER-02 trial (NCT03581786). Bruce also expressed her preference for OS as the gold standard for determining the efficacy of nasopharyngeal cancer treatments and noted the need for more US-based trials to reflect the local patient population.

Artificial Intelligence in Industry with Daniel Faggella
AI ROI for Faster Recruitment and Better Eligibility Rates in Clinical Trials - with Michael Zaiac of Daiichi Sankyo

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Jul 9, 2025 25:12


Today's guest is Michael Zaiac, Head of Medical Oncology for Europe and Canada at Daiichi Sankyo. Michael joins the platform in a special episode focused on how AI is driving measurable ROI in clinical trials—particularly in patient recruitment and eligibility. Their conversation explores how life sciences teams are applying advanced analytics to accelerate enrollment, improve diversity in study populations, and reduce time to trial completion. Michael also shares where generative AI is beginning to play a role in patient-facing materials, including simplified consent forms and study summaries. Throughout the episode, Michael emphasizes the importance of early stakeholder alignment, regulatory transparency, and the discipline required to deploy AI responsibly in high-risk clinical environments. This episode is sponsored by Medable. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!

Oncology Peer Review On-The-Go
S1 Ep169: Best Practices for the Medical Oncology Boards

Oncology Peer Review On-The-Go

Play Episode Listen Later Jul 7, 2025 16:44


The medical oncology board examinations are a pivotal time in a clinician's career. However, preparing for and taking this exam comes as a crucial moment when residents/fellows begin their transition to attending.  While in theory, the process of taking an exam and then beginning a new job sounds simple, it is quite complex. The hematology/oncology boards require rigorous preparation. The exam is followed by the new attending position, where clinicians, for the first time, are on their own, making treatment decisions and leading a team.  ONCOLOGY® spoke with leading clinicians as well as those who are just beginning their careers about this time, and how they handled studying while experiencing personal and professional changes. Eric K. Singhi, MD, assistant professor in the Department of General Oncology, Division of Cancer Medicine, and assistant professor in the Department of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, focused on: ·      His transition from fellow to attending (0:58) ·      Where students should focus their efforts on studying (2:11) ·      Advice he would give to those currently studying (2:47) Nicholas James Hornstein, MD, PhD, assistant professor at Northwell Health Cancer Institute, discussed:  ·      Studying for the boards while balancing a new career (3:18) ·      Specific study areas the exam focuses on (5:43) Marc J. Braunstein, MD, associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine, fellowship program director in hematology/oncology at NYU Langone Health - Long Island, and codirector of the Hematology-Oncology System at NYU Grossman Long Island School of Medicine, highlighted: ·      How to prepare fellows for the career transition (7:11) ·      Advice he gives about this transition (8:17) Nerea M. Lopetegui-Lia, MD, assistant professor in the College of Medicine at The Ohio State University Comprehensive Cancer Center-The James, spoke about: ·      Best review practices for the exam (9:01) ·      Advice she would give to those studying (10:15) MinhTri Nguyen, MD, a medical oncologist with Stanford Medicine, focused on:  ·      As a leadership coach, helping prepare residents/fellows for the career transition (11:36) ·      Advice he would give to those studying (14:34)

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
Episode 45: "Spotlight on Medical Oncology" with Sandy Kotiah, MD

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Jun 30, 2025 52:09


One of the key aspects of one's neuroendocrine cancer care is building your medical team, which typically includes a medical oncologist. In this episode, Medical Oncologist Dr. Sandy Kotiah from Mercy Medical Center in Baltimore expounds on the role of a medical oncologist. She sheds light on the first appointment, communication, and care coordination. TOP TEN QUESTIONSWhat is your role in the neuroendocrine cancer world? What is your role with your medical team?What is a medical oncologist? What training is involved? Is a medical oncologist the same thing as a hematologist oncologist? What's the difference between a medical oncologist & surgical oncologist (& radiation oncologist)?What is a NET expert and how does someone become a NET expert?When I'm looking for a NET expert, what type of doctor am I looking for? How do I know if I'm with a “NET expert”? If I call a medical institution, will I automatically get assigned to a “NET expert?” If someone tells me they are a “NET expert,” does that mean that person is a NET expert?What can I expect on my first appointment? What type of information do you try to communicate with your patients during the first appointment? Newly diagnosed patients often come to their first appointment feeling scared and overwhelmed. They wonder “how long do I have,” worry about how fast the cancer is growing, and are unsure of what to tell their family and friends. How do you address these concerns?What questions should I be asking my oncologist?When/how often should I see my medical oncologist? Who goes over my scan results with me? When does that happen/How soon after a scan should I expect results? Who communicates the tumor board discussions?How is care coordinated with other providers on my team within the same institution? How is care coordinated with other providers from different institutions (i.e. with a local oncologist and a NET expert)?What happens if someone wants a second opinion? How do you feel about second opinions?How do I navigate or work through a situation in which there are differing opinions between doctors? If I have a question, concern, or symptoms, who do I communicate with and what's the best way to communicate? What if we “run out of time” during an appointment? What if it's a question or concern I'm shy about communicating?Some people struggle with trust because of past experiences with providers who might have ignored or minimized their symptoms. What advice do you have to help build trust with my doctor? What would you say is my responsibility as a patient and your responsibility as the oncologist? If there is one thing you would like all people living with neuroendocrine cancer to know, what would it be?For more information, visit NCF.net.

Oncology for the Inquisitive Mind
162. ASCO 2025 - Genitourinary Cancers (Prostate) with Dr. Anthony Joshua

Oncology for the Inquisitive Mind

Play Episode Listen Later Jun 16, 2025 34:52


Today, we're joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent's Hospital, Sydney, and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses multiple trials including AMPLITUDE, advancing prostate cancer therapies; CAN 2409, exploring immunotherapy; ARANOTE, showing darolutamide's impact on progression-free survival; the prognostic significance of PSA 0.2; and the landmark STAMPEDE study. Join us for a deep dive into these game-changing studies. Let's begin! It's a jam-packed episode!Studies discussed in the episode:AMPLITUDECAN2409ARANOTESTAMPEDE*AND MORE!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

QuadShot News Podcast
6.9.2025 - NIVONEWS

QuadShot News Podcast

Play Episode Listen Later Jun 9, 2025 10:21


Check out this week's QuadCast with many highlights from ASCO, including adding nivo to postop CRT in HNSCC, the benefits of immunotherapy in resected MMRd colon cancer, how SRS beat HA-WBRT, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Research To Practice | Oncology Videos
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 2, 2025 47:56


Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, including the following topics: Systemic Mastocytosis — Dr Bose (0:00) Myelofibrosis — Dr Kuykendall (24:46) CME information and select publications

Hematologic Oncology Update
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

Hematologic Oncology Update

Play Episode Listen Later Jun 2, 2025 47:55


Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis.  CME information and select publications here.

Research To Practice | Oncology Videos
Hepatocellular Carcinoma — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Jun 1, 2025 51:05


Featuring perspectives from Dr Thomas A Abrams and Dr Ahmed Omar Kaseb, including the following topics: Current Treatment for Advanced Hepatocellular Carcinoma (HCC) — Dr Abrams (0:00) Promising Novel Approaches to HCC Management — Dr Kaseb (33:46) CME information and select publications

Gastrointestinal Cancer Update
Hepatocellular Carcinoma — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later Jun 1, 2025 51:04


Clinical investigators discuss available data guiding the management of hepatocellular carcinoma.  CME information and select publications here.

Gastrointestinal Cancer Update
Hepatocellular Carcinoma — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later Jun 1, 2025 51:04


Clinical investigators discuss available data guiding the management of hepatocellular carcinoma.  CME information and select publications here.

Research To Practice | Oncology Videos
Multiple Myeloma — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 31, 2025 50:41


Featuring perspectives from Dr Natalie S Callander and Dr Thomas Martin, including the following topics: Introduction (0:00) Current and Emerging Therapeutic Approaches for Multiple Myeloma — Dr Callander (4:42) CAR T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Martin (31:16) CME information and select publications

Hematologic Oncology Update
Multiple Myeloma — Fourth Annual National General Medical Oncology Summit

Hematologic Oncology Update

Play Episode Listen Later May 31, 2025 50:41


Clinical investigators discuss available data guiding the management of multiple myeloma.  CME information and select publications here.

Research To Practice | Oncology Videos
Gastroesophageal Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 26, 2025 52:33


Featuring perspectives from Dr Yelena Y Janjigian and Dr Samuel J Klempner, MD, including the following topics: Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Janjigian (0:00) Available and Emerging Targeted Therapeutic Approaches for Gastroesophageal Cancers — Dr Klempner(28:38) CME information and select publications

Gastrointestinal Cancer Update
Gastroesophageal Cancer — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later May 26, 2025 52:32


Clinical investigators discuss available data guiding the management of gastroesophageal cancer.  CME information and select publications here.

Gastrointestinal Cancer Update
Gastroesophageal Cancer — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later May 26, 2025 52:32


Clinical investigators discuss available data guiding the management of gastroesophageal cancer.  CME information and select publications here.

TALRadio
Radiation Therapy Demystified What Patients Should Really Know | Special Interview With Dr.K.C.Goutham Reddy

TALRadio

Play Episode Listen Later May 24, 2025 36:16


Radiation Therapy can seem daunting, but it doesn't have to be. Tune in to TALRadio English on Spotify & Apple Podcasts for a compelling interview with Dr. K.C. Goutham Reddy, Senior Consultant Oncologist and Founder & Managing Director of Cancer Shield Pvt Ltd. With a rich background in Medical Oncology, Radiation Oncology, and Palliative Care, Dr. Reddy shares valuable insights into the role of radiation therapy in cancer treatment, addressing common myths, clinical facts, and patient-centered approaches. Hosted by Suhasini, this episode offers clarity and confidence to those facing cancer.Host : SuhasiniGuest : K.C.Goutham ReddyYou Can Reach K.C.Goutham Reddy @linkedin.com/in/k-c-goutham-reddy-534b183b#TALRadioEnglish #CancerCare #RadiationTherapy #Oncology #HealthcareLeadership #PatientSupport #TALHospitals #MedicalOncology #PalliativeCare #CancerAwareness #HolisticHealing #ClinicalInsight #TouchALife #TALRadio

Research To Practice | Oncology Videos
Urothelial Bladder Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 22, 2025 49:02


Featuring perspectives from Dr Shilpa Gupta and Dr Jonathan E Rosenberg, including the following topics: Management of Nonmetastatic Urothelial Bladder Cancer (UBC) — Dr Gupta (0:00) Optimizing the Treatment of Metastatic UBC — Dr Rosenberg (21:52) CME information and select publications

Prostate Cancer Update
Urothelial Bladder Cancer — Fourth Annual National General Medical Oncology Summit

Prostate Cancer Update

Play Episode Listen Later May 22, 2025 49:01


Clinical investigators discuss available data guiding the management of urothelial bladder cancer.  CME information and select publications here.

Research To Practice | Oncology Videos
Pancreatic Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 21, 2025 49:14


Featuring perspectives from Dr Paul E Oberstein and Dr Philip A Philip, including the following topics: Selection and Sequencing of Therapy for Patients with Metastatic Pancreatic Adenocarcinoma (PAD) — Dr Oberstein (0:00) Biomarker-Based Strategies for Metastatic PAD; Novel Investigational Approaches — Dr Philip(30:57) CME information and select publications

Gastrointestinal Cancer Update
Pancreatic Cancer — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later May 21, 2025 49:14


Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

Gastrointestinal Cancer Update
Pancreatic Cancer — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later May 21, 2025 49:14


Clinical investigators discuss available data guiding the management of pancreatic cancer.  CME information and select publications here.

OncLive® On Air
S13 Ep2: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

OncLive® On Air

Play Episode Listen Later May 19, 2025 49:30


This featured podcast includes a discussion with 3 experts on managing patients with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) from a satellite symposium held in conjunction with the 42nd Annual Miami Breast Cancer Conference® in March 2025. In observational studies of treatment patterns in older women with mBC, approximately half of the patients were undertreated, and only half received a CDK4/6 inhibitor (CDK4/6i)-based regimen in the first-line setting. Reasons for undertreatment include concerns about the patient's age, perceived frailty, and underlying health issues. Aging is a heterogeneous process; older patients must receive individualized treatment that is not based solely on their age but on a comprehensive assessment that objectively assesses their overall health and ability to tolerate treatment. This program is designed to help clinicians assess the fitness of older patients with HR+/HER2– mBC, review the efficacy and safety of CDK4/6i in this patient population, and individualize treatment decision-making appropriately. Acknowledgment of Educational Grant Support This activity is supported by an educational grant from Pfizer Inc. Today's faculty are: Hope S. Rugo, MD Director, Women's Cancers Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Duarte, CA Professor Emeritus, UCSF Disclosures: Grant/Research Support: Ambrx; AstraZeneca; Daiichi Sankyo, Inc; F. Hoffmann-La Roche AG/Genentech, Inc; Gilead Sciences, Inc; Lilly; Merck & Co., Inc; Novartis Pharmaceuticals Corporation; OBI Pharma; Pfizer; Stemline Therapeutics. Consultant: Napo Therapeutics; Puma Biotechnology; Sanofi. Honoraria: Chugai; Mylan/Viatris. Neil M. Iyengar, MD Associate Attending, Breast Medicine Service Program Lead, MSK Healthy Living Department of Medicine Memorial Sloan Kettering Cancer Center Associate Professor of Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Adviser: Arvinas, AstraZeneca, BD Life Sciences, Daiichi Sankyo, Genentech/Roche, Gilead, Menarini-Stemline, Novartis, Pfizer, Puma, Seagen, TerSera Therapeutics. Speaker: Cardinal Health, Curio Sciences, DAVA Oncology, IntrinsiQ Health. Editorial Position: npj Breast Cancer, Oncology®. Equity/Ownership: Complement Theory, Bettering Company. Research Support (to institution): American Cancer Society, Breast Cancer Research Foundation, Conquer Cancer Foundation, Kat's Ribbon of Hope, National Cancer Institute/National Institutes of Health. Contracted Research: Novartis, SynDevRx. Komal Jhaveri, MD, FACP Patricia and James Cayne Chair for Junior Faculty Associate Attending Physician, Breast Medicine Service and Early Drug Development Service Section Head, Endocrine Therapy Research Program Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center Associate Professor of Clinical Medicine Weill Cornell Medical College New York, NY Disclosures: Consultant/Advisory Board: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jounce Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Novartis, Olema Oncology, Pfizer Inc, Scorpion Therapeutics, Seagen Inc, Stemline Therapeutics Inc, Sun Pharma Advanced Research Company Ltd, Taiho Oncology Inc. Research Funding: AstraZeneca Pharmaceuticals LP, Debiopharm, Genentech, a member of the Roche Group, Gilead Sciences Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Scorpion Therapeutics, Zymeworks Inc. The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process. Off-Label Disclosure and Disclaimer This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Chicago's Afternoon News with Steve Bertrand
What does President Biden's diagnosis mean?

Chicago's Afternoon News with Steve Bertrand

Play Episode Listen Later May 19, 2025


Fahad Faruqi, MD, Doctor of Hematology and Medical Oncology at Northwestern Medicine, joins Lisa Dent to discuss former President Biden’s prostate cancer diagnosis. Dr. Faruqi discusses the difference between ‘terminal’ and ‘incurable’ and what it means for Biden’s health.

Research To Practice | Oncology Videos
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 18, 2025 50:15


Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics: Introduction (0:00) Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04) First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation — Dr Liu (26:59) CME information and select publications

Lung Cancer Update
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit

Lung Cancer Update

Play Episode Listen Later May 18, 2025 50:15


Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches.  CME information and select publications here.

Research To Practice | Oncology Videos
Colorectal Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 17, 2025 50:09


Featuring perspectives from Dr Christopher Lieu and Dr Kanwal Raghav, including the following topics: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Dr Lieu (0:00) Recent Advances in the Management of Metastatic CRC — Dr Raghav (32:58) CME information and select publications

Gastrointestinal Cancer Update
Colorectal Cancer — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later May 17, 2025 50:09


Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Gastrointestinal Cancer Update
Colorectal Cancer — Fourth Annual National General Medical Oncology Summit

Gastrointestinal Cancer Update

Play Episode Listen Later May 17, 2025 50:09


Clinical investigators discuss available data guiding the management of colorectal cancer.  CME information and select publications here.

Research To Practice | Oncology Videos
Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 12, 2025 50:04


Featuring perspectives from Dr Christopher Flower and Dr Krish Patel, including the following topics: Role of Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Non-Hodgkin Lymphoma (NHL) — Dr Patel (0:00) Other Available and Emerging Novel Therapies for NHL — Dr Flowers (22:07) CME information and select publications

Hematologic Oncology Update
Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit

Hematologic Oncology Update

Play Episode Listen Later May 12, 2025 50:03


Clinical investigators discuss available data guiding the management of non-Hodgkin lymphoma.  CME information and select publications here.

The Breast Cancer Podcast
A Mother's Heart: Nurturing Others, Nourishing Herself

The Breast Cancer Podcast

Play Episode Listen Later May 11, 2025 32:12


On this Mother's dray, we honor the heart of every mother — the love she gives, the sacrifices she makes, and the quiet strength she carries every single day. But today, we also pause to ask: how can mothers take care of themselves? How can faith and medicine guide them to nurture not just others, but their own beautiful, essential selves? Whether you are a mother, lost a mother, hope to be one, or are simply someone who has been touched by the love of a mother, this episode is for you. Together, let's explore what it means to mother others — and to mother ourselves — through the lens of both faith and wellness.Please join my two special guests on the podcast:Dr. Shabana Dewani  is board certified in Medical Oncology, Hematology, and Internal Medicine—and a joy to listen to!  You'll be able to hear her passion for how takes care of herself and advocates for other mothers. Pastor Jennifer Jackson offers faith perspective and self care for women. She provides us her learnings as she went through her own breast cancer diagnosis.  She strives to help women through life, whether it's a book, her own radio show, or by mentoring them.  You'll be uplifted by our discussion with Jennifer she talks about what faith says about women taking care of themselves.Learn More About Jennifer Jackson here.InstagramFacebookIf you want to buy my book, click the link below.Their Legacy, Their Light She Carries: A Breast Surgeon's Mission to Serve and Inspire HopeStay Connected with Dr. Deepa Halaharvi:TikTok: @breastdoctorInstagram: @drdhalaharviTBCP Instagram: @thebreastcancerpodcastWebsite: https://drdeepahalaharvi.com/YouTube: https://www.youtube.com/@deepahalaharvi5917Instagram: @thebreastcancerpodcast

Research To Practice | Oncology Videos
Gynecologic Cancers — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later May 11, 2025 48:42


Featuring perspectives from Dr David M O'Malley and Dr Brian M Slomovitz, including the following topics: Ovarian Cancer; HER2-Directed Therapy for Advanced Gynecologic Cancers — Dr O'Malley (0:00) Endometrial Cancer and Cervical Cancer — Dr Slomovitz (23:38) CME information and select publications

D.O. or Do Not: The Osteopathic Physician's Journey for Premed & Medical Students
Episode 152: Dr. Anna Levy, D.O. - Hematology/ Oncology- Director of Hepato-billiary Malignancies at NorthWell Health!

D.O. or Do Not: The Osteopathic Physician's Journey for Premed & Medical Students

Play Episode Listen Later May 6, 2025 40:20


Send us a textIn today's episode we have the pleasure of speaking to Dr. Anna Levy, D.O.   Dr. Levy is an oncologist who works in the very specialized area of liver related cancers.  Dr. Levy is Medical Director of Hepatobiliary Malignancies and the Hepatic Artery Pump Infusion Program, based at the R.J. Zuckerberg Cancer Center.   Dr Levy is  is Board certified in Internal Medicine, Hematology, and Medical Oncology.  She is  Assistant Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health Medical School.  Dr. Levy earned her medical degree at the Lake Erie College of Osteopathic Medicine followed by an Internal Medicine Residency at the Christiana Care Health System and ultimately completed her fellowship in Medical Oncology and Hematology at the Long Island Jewish Medical Center.Dr. Levy will delve into the life of an oncologist and the difficulties treating very sick patients.  She will discuss the difficulties of work life balance and how her family and home life allow her to “keep her cup full."  Dr. Levy will discuss the problem of suicide, among physicians specifically among high stress professions such as Hematology/ Oncology.  Dr. Levy will share her journey which started as an emigre from the Ukraine.  She will tell us about her discovery of Osteopathic Medicine and how she developed a  love for oncology, a difficult and complex specialty.  Please join us in our discussion with this  remarkable physician. . . a discussion you won't want to miss!

OncLive® On Air
S12 Ep45: RP1 Plus Nivolumab Delivers Durable Responses in PD-1–Exposed Melanoma: With Anna C. Pavlick, BSN, MSc, DO, MBA

OncLive® On Air

Play Episode Listen Later May 5, 2025 10:56


In today's episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. In our exclusive interview, Dr Pavlick discussed the rationale for investigating this combination in patients with advanced melanoma who have received prior immune checkpoint inhibition, key efficacy and safety findings from the phase 1/2 IGNYTE trial (NCT03767348), and where the future may be headed regarding the use of oncolytic viruses in melanoma.

Research To Practice | Oncology Videos
Prostate Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 29, 2025 47:34


Featuring perspectives from Dr Rahul Aggarwal and Dr William K Oh, including the following topics: Hormonal Therapy for Patients with Prostate Cancer — Dr Oh (0:00) Other Available and Emerging Therapeutic Approaches — Dr Aggarwal (27:14) CME information and select publications

Dr. Tamara Beckford Show
Charting Made Easy for Physicians

Dr. Tamara Beckford Show

Play Episode Listen Later Apr 28, 2025 38:30


Are you a physician overwhelmed by late-night charting? Dr. Mary Leung, board-certified in internal medicine, medical oncology, and hematology — and now a certified life coach — knows your struggle firsthand.Dr. Mary completed her medical education at the University at Buffalo School of Medicine. She went on to complete her residency in Internal Medicine and her fellowship in Hematology and Medical Oncology at the Zucker School of Medicine at Hofstra/Northwell. Her solid clinical background, combined with her experience as a certified life coach, gives her a unique and compassionate perspective on physician burnout and well-being.In this empowering livestream, discover how Dr. Mary went from burnout and after-hours charting to confidently finishing her clinical day on time. Learn the exact tools and mindset shifts that transformed her routine and helped her rediscover joy in medicine.✅ Why charting was draining her energy✅ How coaching transformed her time and mindset✅ How she helps physicians regain control, clarity, and time✅ Steps to build a meaningful, sustainable medical careerDr. Mary founded Shining With Gratitude MD to guide physicians through their unique journeys. Her mission: help doctors feel better, live fuller lives, and fall in love with medicine again.Connect with Dr. MaryLinkedIn Mary Leung, MDFacebook Mary LeungWebsite https://www.shiningwithgratitudemd.com

Research To Practice | Oncology Videos
Biliary Tract Cancers — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 27, 2025 48:55


Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics: Introduction (0:00) Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59) Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16) CME information and select publications

Research To Practice | Oncology Videos
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 20, 2025 52:18


Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics: Introduction (0:00) Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42) Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC — Dr Goldman (37:25) CME information and select publications

Research To Practice | Oncology Videos
HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit

Research To Practice | Oncology Videos

Play Episode Listen Later Apr 19, 2025 99:35


Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O'Shaughnessy, including the following topics: Introduction (0:00) HER2-Positive Breast Cancer — Dr O'Shaughnessy (3:13) Triple-Negative Breast Cancer — Dr Bardia (32:56) Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35) Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15) CME information and select publications

The Plant Free MD with Dr Anthony Chaffee: A Carnivore Podcast
Episode 275: Quantum Health Beyond Carnivore

The Plant Free MD with Dr Anthony Chaffee: A Carnivore Podcast

Play Episode Listen Later Apr 14, 2025 67:26


The premise behind the Carnivore Diet is to eat to our biological design: exposing ourselves to the beneficial and essential nutrients, and removing the harmful exposures.  However there are more essential and beneficial exposures beyond just meat, and there are harmful exposures besides plant toxins.  This episode takes a closer look beyond the best ditary exposures to what are some of the best overall exposures for your health as well.  Enjoy! Dr. Petra Davelaar is a naturopathic doctor specializing in Deutenomic medicine—a field that explores the role of deuterium (a heavy isotope of hydrogen) in human health. Her work focuses on how deuterium levels affect cellular processes, particularly mitochondrial function, and how reducing deuterium accumulation may support disease prevention and recovery. ​ Born and raised in the Netherlands, Dr. Davelaar moved to New York in her 20s. She earned her Doctor of Naturopathic Medicine degree from Bastyr University in California in 2016. After practicing in Santa Monica for several years, she now offers consultations via telemedicine. Since January 2021, her credentials have been recognized in Hungary and most other European countries. ​ Dr. Davelaar is also certified in functional medicine and nutrition. She has served as a peer reviewer for scientific journals such as Scientific Reports and Medical Oncology. ​ In addition to her clinical work, Dr. Davelaar has contributed to public education through lectures and podcasts, discussing topics like deuterium depletion, over-hydration, and their implications for health and disease. ​ For more information about her work or to schedule a consultation, you can visit her official website at drpetrad.com